DT
HealthMore in Health→
Experimental pancreatic cancer drug points to a rare survival gain in a hard-to-treat disease
Key Takeaways
- The supplied source says pancreatic cancer remains among the deadliest and hardest cancers to treat.
- A Northwestern-developed drug reportedly doubled one-year survival in a trial.
- The available text is limited, so the result should be viewed as promising but still in need of fuller validation.
DE
DT Editorial Team··via medicalxpress.com